It was reported that high expression of IGF2BP3 in patients with glioma significantly reduced survival time, which was also associated with poor prognosis, suggesting that IGF2BP3 might be used as a potential prognostic biomarker for gliomas (Liu et al., 2021b; Sun et al., 2021; Xiong et al., 2022). This evidence concerns the gene IGF2BP3 and glioma.